Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Texas Oncology, P.A.
mi
from
Bedford, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Texas Oncology, P.A.
mi
from
Bedford, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Texas Oncology, P.A. Texas Oncology - Sugar Land
mi
from
Dallas, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Texas Oncology, P.A. Texas Oncology - Sugar Land
mi
from
Dallas, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp
mi
from
Dallas, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp
mi
from
Dallas, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
MD Anderson Cancer Center/University of Texas
mi
from
Houston, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
MD Anderson Cancer Center/University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Baylor College of Medicine Baylor College of Medicine (3)
mi
from
Houston, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Baylor College of Medicine Baylor College of Medicine (3)
mi
from
Houston, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So.TX- MedicalCenter(2)
mi
from
San Antonio, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So.TX- MedicalCenter(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
University of Arkanasas for Medical Sciences UAMS
mi
from
Little Rock, AR
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
University of Arkanasas for Medical Sciences UAMS
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
H. Lee Moffitt Cancer Center/University of South Florida SC - 3
mi
from
Tampa, FL
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
H. Lee Moffitt Cancer Center/University of South Florida SC - 3
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
mi
from
Atlanta, GA
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Indiana University Indiana Univ
mi
from
Indianapolis, IN
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Indiana University Indiana Univ
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Dana Farber Cancer Institute DFCI (2)
mi
from
Boston, MA
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Dana Farber Cancer Institute DFCI (2)
mi
from
Boston, MA
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Washington University School Of Medicine-Siteman Cancer Ctr Dept. of WUSTL
mi
from
St. Louis, MO
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Washington University School Of Medicine-Siteman Cancer Ctr Dept. of WUSTL
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Hackensack University Medical Center Multiple Myeloma Division
mi
from
Hackensack, NJ
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Hackensack University Medical Center Multiple Myeloma Division
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Mount Sinai School of Medicine Mt Sinai
mi
from
New York, NY
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Mount Sinai School of Medicine Mt Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Duke University Medical Center Duke SC
mi
from
Durham, NC
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Duke University Medical Center Duke SC
mi
from
Durham, NC
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Cancer Therapy & Research Center / UT Health Science Center CTRC 2
mi
from
San Antonio, TX
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Cancer Therapy & Research Center / UT Health Science Center CTRC 2
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated:  7/19/2012
Fred Hutchinson Cancer Research Center Fred Hutchinson
mi
from
Seattle, WA
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma
Status: Enrolling
Updated: 7/19/2012
Fred Hutchinson Cancer Research Center Fred Hutchinson
mi
from
Seattle, WA
Click here to add this to my saved trials
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity
Status: Enrolling
Updated:  7/25/2012
Children's Hospital of Michigan
mi
from
Detroit, MI
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity
Status: Enrolling
Updated: 7/25/2012
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML
Status: Enrolling
Updated:  7/30/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML
Status: Enrolling
Updated: 7/30/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  7/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 7/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Click here to add this to my saved trials
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated:  8/5/2012
Georgetown University
mi
from
Washington,
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated: 8/5/2012
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated:  8/5/2012
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated: 8/5/2012
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated:  8/5/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated: 8/5/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated:  8/5/2012
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated: 8/5/2012
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated:  8/5/2012
Vanderbilt University
mi
from
Nashville, TN
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated: 8/5/2012
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated:  8/5/2012
Puget Sound Blood Center
mi
from
Seattle, WA
Hemophilia Adult Prophylaxis Study
R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A
Status: Enrolling
Updated: 8/5/2012
Puget Sound Blood Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated:  8/7/2012
University of Arizona, Infectious Disease Research
mi
from
Tuscon, AZ
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated: 8/7/2012
University of Arizona, Infectious Disease Research
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated:  8/7/2012
UCLA Clinical Laboratory
mi
from
Los Angeles, CA
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated: 8/7/2012
UCLA Clinical Laboratory
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated:  8/7/2012
Medical University of South Carolina
mi
from
Charleston, SC
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA
Status: Enrolling
Updated: 8/7/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
Status: Enrolling
Updated:  8/9/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
Status: Enrolling
Updated: 8/9/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
Survey of X-Linked Hypohidrotic Ectodermal Dysplasia Carrier Women's Outlook Towards Reproduction, Potential XLHED Treatments and Genetic Testing
Status: Enrolling
Updated:  8/20/2012
Carrie Milliard
mi
from
Portland, ME
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
Survey of X-Linked Hypohidrotic Ectodermal Dysplasia Carrier Women's Outlook Towards Reproduction, Potential XLHED Treatments and Genetic Testing
Status: Enrolling
Updated: 8/20/2012
Carrie Milliard
mi
from
Portland, ME
Click here to add this to my saved trials
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia
Status: Enrolling
Updated:  8/22/2012
Univ of Massachusetts Med School
mi
from
Worcester, MA
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia
Status: Enrolling
Updated: 8/22/2012
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Arizona Clinical Research Center, Inc. / Arizona Oncology Associates, 1825 N Kolb,
mi
from
Tucson, AZ
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Arizona Clinical Research Center, Inc. / Arizona Oncology Associates, 1825 N Kolb,
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Pacific Shores Medical Group 1043 Elm Ave, Suite 104
mi
from
Long Beach, CA
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Pacific Shores Medical Group 1043 Elm Ave, Suite 104
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
UCLA Medical Center Hematology / Oncology Division, 10945 Le Conte Ave #2333,
mi
from
Los Angeles, CA
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
UCLA Medical Center Hematology / Oncology Division, 10945 Le Conte Ave #2333,
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Collaborative Research Group 2320 S Seacrest Blvd, Suite 202
mi
from
Boynton Beach, FL
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Collaborative Research Group 2320 S Seacrest Blvd, Suite 202
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Florida Cancer Institue New Hope Clinic 8763 River Crossing Blvd.
mi
from
New Port Richey, FL
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Florida Cancer Institue New Hope Clinic 8763 River Crossing Blvd.
mi
from
New Port Richey, FL
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Rush University Medical Center / Division of Hematology/Oncology Research 1725 W Harrison Street, Suite 834
mi
from
Chicago, IL
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Rush University Medical Center / Division of Hematology/Oncology Research 1725 W Harrison Street, Suite 834
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Cancer Institute of New Jersey 195 Little Albany Street
mi
from
New Brunswick, NJ
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Cancer Institute of New Jersey 195 Little Albany Street
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Piedmont Hematology Oncology Associates, PLLC 1010 Bethesda Court
mi
from
Winston-Salem, NC
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Piedmont Hematology Oncology Associates, PLLC 1010 Bethesda Court
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
The Jones Clinic 7710 Wolf River Circle
mi
from
Germantown, TN
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
The Jones Clinic 7710 Wolf River Circle
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
UT MD Anderson Cancer Center, 1515 Holcombe Boulevard,
mi
from
Houston, TX
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
UT MD Anderson Cancer Center, 1515 Holcombe Boulevard,
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N.,
mi
from
Seattle, WA
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N.,
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Gundersen Clinic Center for Cancer and Blood Disorders, 1900 South Ave, EB2-001,
mi
from
La Crosse, WI
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Gundersen Clinic Center for Cancer and Blood Disorders, 1900 South Ave, EB2-001,
mi
from
La Crosse, WI
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Long Beach Memorial
mi
from
Long Beach, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Long Beach Memorial
mi
from
Long Beach, CA
Click here to add this to my saved trials